Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04719832 · ClinicalTrials.gov registry record · Phase 3
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 395
- Enrollment target
NCT04719832 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 395 participants.
The verdict
NCT04719832, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 395 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an eosinophilic phenotype
Interventions
- DRUG Placebo
- BIOLOGICAL GSK3511294 (Depemokimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2023-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04719832
The ClinicalTrials.gov registry entry for NCT04719832 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04719832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04719832 about?
NCT04719832 is a clinical study titled "Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype". This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an eosinophilic phenotype
What is the current status of trial NCT04719832?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 395 participants. The study started on 2021-03-17. Estimated completion is 2023-11-21.
What interventions are being tested in trial NCT04719832?
The interventions under investigation include: Placebo (DRUG), GSK3511294 (Depemokimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04719832?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.